- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 613KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 138KB)
Selinexor – July 2021
Selinexor (DLBCL): Tablet 20 mg; Xpovio®
Last updated
30 May 2025